

COMPLETE LISTING OF CLAIMS

1. (Currently Amended) An isolated antibody that is raised against and specifically binds one or more peptide selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
2. (Currently Amended) The isolated antibody of Claim 1, wherein said antibody is a monoclonal antibody.
3. (Previously Presented) The antibody of Claim 1, wherein said antibody specifically binds the peptide Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1).
4. (Previously Presented) The antibody of Claim 2, wherein said antibody specifically binds the peptide Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1).
5. (Previously Presented) The antibody of Claim 1, wherein said antibody specifically binds the peptide Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4).
6. (Previously Presented) The antibody of Claim 2, wherein said antibody specifically binds the peptide Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4).
7. (Previously Presented) The antibody of Claim 1, wherein said antibody specifically binds the peptide Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
8. (Previously Presented) The antibody of Claim 2, wherein said antibody specifically binds the peptide Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

9. (Original) The antibody of Claim 1, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

10. (Original) The antibody of Claim 2, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Currently Amended) An immunoassay method for detecting a peptide in a sample of body fluid, comprising the steps of contacting the test sample with ~~an~~ the isolated antibody according to Claim 1, and determining binding thereof to said peptide in the test sample, wherein said one or more peptide is selected from the group consisting of: Phe-Phe-Gly-

Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

25. (Previously Presented) The immunoassay method of Claim 24, wherein said body fluid comprises blood.

26. (Previously Presented) The immunoassay method of Claim 24, wherein said peptide is labeled, and said antibody is conjugated to a solid phase, whereby a competitive assay can be performed by exposing said antibody-solid phase conjugate to the test sample and the amount of analyte associated with the solid phase is measured using the labeled peptide.

27. (Previously Presented) The immunoassay method of Claim 26, wherein said label is one or more of a radioactive label, fluorescent label, biological label and enzymatic label.

28. (Previously Presented) A diagnostic reagent or kit comprising the antibody of Claim 1.

29. (New) A method of producing the isolated antibody of Claim 1, comprising:

- a) immunizing an animal with a peptide, wherein said peptide is selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2);
- b) harvesting antibody-producing B cells from said animal;
- c) fusing said antibody-producing B cells with a myeloma cell line; and
- d) culturing said fused cells under conditions that allow the production of said antibody.

30. (New) A hybridoma that produces the antibody according to Claim 2.

31. (New) The isolated antibody of Claim 1, further wherein the antibody has no significant reactivity to tachykinins of mammalian origin.